Hanshang Group’s announcement on the 2026 action plan of “Improving Quality, Increasing Efficiency and Focusing on Returns”
Securities code: 600774 Stock abbreviation: Hanshang Group Announcement number: 2026-018
Hanshang Group Co., Ltd.
Announcement on the 2026 Action Plan of “Improving Quality, Increasing Efficiency and Focusing on Returns”
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
In order to thoroughly implement the spirit of the Central Economic Work Conference and the Central Financial Work Conference, implement the requirements of the State Council's "Opinions on Further Improving the Quality of Listed Companies", actively respond to the Shanghai Stock Exchange's "Initiative on Carrying out the Special Action of "Improving Quality, Increasing Efficiency and Focusing on Returns" for Shanghai Stock Exchange Companies, practice the "investor-oriented" development concept, promote high-quality development of companies and increase investment value, and protect the legitimate rights and interests of investors, especially small and medium-sized investors. Hanshang Group Co., Ltd. has formulated this action plan based on its own operating reality, development strategy and core competitiveness. The specific contents are as follows:
1. Focus on the development of dual main businesses and improve the quality of operations
The company will continue to implement the dual-main business development strategy of "big health + big commerce" to further improve the operational quality and efficiency of each business segment. In the big health sector, Dikang Pharmaceutical focuses on the three core areas of chemical drugs, Chinese patent medicines and medical devices to stabilize production and expand sales, deeply tap the potential of existing products, and increase the sales scale of potential products. Dikang Zhongke consolidates its technical advantages in medical-grade polylactic acid materials and promotes the industrialization of medical aesthetics and sports medicine products such as polylactic acid microspheres. Huake Reproductive Hospital continues to promote the construction of new campuses and extend the assisted reproductive service chain. In the large commercial sector, the company's various commercial entities continue to promote "clearing empty spaces, upgrading business formats, and renewing brands", focusing on customer groups of all ages, focusing on experiential consumption such as catering, education and entertainment, and accelerating upgrading. In 2025, 10 low-altitude logistics routes have been approved. In 2026, we will continue to explore the in-depth integration of low-altitude economy and commercial operations to expand the scale of high-time-efficiency commodity distribution business. At the same time, the online and offline integrated media promotion platform will be optimized to expand brand influence. In the exhibition sector, we will improve the ecological construction of "exhibition + industry", focus on new energy themed exhibition platforms, continue to promote the linkage and staggered development of the two venues, and expand the scale of self-organized exhibitions.
2. Accelerate the development of new productive forces and strengthen innovation-driven development
The company adheres to the concept of driving technology innovation, continues to increase investment in R&D in the fields of drugs and medical devices, and accelerates the development of new productivity. In terms of innovative drugs, the company has complete independent intellectual property rights for global Class I innovative drugs. The DDCI-01 project is based on two phase II clinical research reports (indications for the rare disease pulmonary arterial hypertension (PAH), and indications for lower urinary tract disease caused by benign prostatic hyperplasia (BPH-LUTS) combined with erectile dysfunction (ED)). Both have completed the EOP2 meeting with the Center for Drug Evaluation (CDE) of the National Medical Products Administration; in accordance with CDE requirements, relevant clinical pharmacological preparations before the launch of phase III clinical trials are being improved. At the same time, after the drug is put on the market, it can highlight the clinical characteristics of having the longest efficacy among similar drugs, and we are exploring the effectiveness data of longer efficacy time after taking the drug to support subsequent clinical development decisions. As a Chinese medicine business development platform, Dikang Traditional Chinese Medicine relies on the company's superior sales resources to continue to enrich its product portfolio and create unique product competitiveness and brand value. In the field of medical devices, we continue to promote the research and development of reserve devices such as absorbable micro-nails and chest and rib nails, and strengthen the technological iteration and industrialization of polylactic acid material-related products. The company attaches great importance to R&D work and keeps R&D investment intensity within a reasonable range to ensure the steady advancement of R&D projects.
3. Improve corporate governance and strengthen standardized operations
The company will continue to improve its corporate governance structure, continuously improve its governance level, and effectively protect the legitimate rights and interests of investors. Improve the corporate governance system, continue to improve the internal governance system, strengthen the functions of the board of directors and various special committees, give full play to the independent supervisory role of independent directors, and ensure that the shareholders' meeting and the board of directors operate in a standardized manner and make scientific decisions. At present, the company has comprehensively and systematically sorted out, revised and improved the Articles of Association and relevant internal control systems in accordance with the latest revised policies and regulations and the relevant normative document requirements of relevant regulatory agencies, further promoting the standardization of corporate governance.
Continuously improve the level of corporate governance through information sharing, division of responsibilities, construction of collaboration mechanisms and improvement of professional capabilities. Strengthen internal control and risk management, continue to improve the construction of the internal control system, and strengthen financial control and risk warning mechanisms. In 2026, the asset structure will be further optimized, the investment decision-making process will be improved, and potential future risks will be reduced.
4. Improve investor returns and enhance investor confidence
The company will actively take measures to effectively protect the interests of investors, improve investor returns, and stabilize the cash dividend policy. On the premise of complying with laws, regulations and the company's articles of association, comprehensively considering the company's actual operating development, profitability and cash flow levels, actively implement dividend distribution in cash, stocks or a combination of cash and stocks.
Strengthen market value management. We will continue to pay attention to the company's stock price performance, and on the premise of complying with laws and regulations, timely study stock price stabilization measures such as share repurchases and increasing holdings by controlling shareholders to enhance investor confidence. In 2024, the controlling shareholder Zall Holdings has implemented a plan to increase its holdings. In 2026, the company will evaluate further market value management measures based on market conditions and funding conditions.
5. Strengthen investor communication and enhance market recognition
The company will continue to strengthen communication with investors, improve the transparency of information disclosure, and enhance the market's understanding and recognition of the company's value. Investor briefings will be carried out on a regular basis. In 2026, the company will continue to actively participate in various performance briefings organized by the Shanghai Stock Exchange and regularly hold investor exchange activities. Enrich investor communication channels. We will continue to strengthen interaction with investors through various forms such as the "SSE e-Interactive" platform, investor relations emails, investor hotlines, and on-site surveys. Establish an investor consultation and feedback mechanism, carefully listen to investors' opinions and suggestions on the company's business development and investor returns, and incorporate reasonable suggestions into the company's business decision-making considerations. Improve the quality of information disclosure, continue to adhere to the principles of true, accurate, complete, timely and fair information disclosure, and improve the readability and transparency of information disclosure.
6. Strengthen the responsibilities of “key minorities” and urge the improvement of their ability to perform their duties
The company strengthens the risk sharing and benefit sharing constraints between controlling shareholders, actual controllers, directors and senior management personnel, the company, and small and medium-sized shareholders. Continue to strengthen the responsibilities of "key minorities", urge them to further improve their ability to perform duties, strengthen compliance awareness, stimulate corporate vitality, and enhance market confidence in the company's development prospects. In 2026, the company will promptly communicate the latest regulatory requirements to controlling shareholders, actual controllers, directors and senior managers through various channels such as emails and work contact groups, regularly organize and participate in various special trainings for listed companies and interpretation of the latest laws and regulations, strengthen the learning of "key minority" personnel on relevant laws, regulations and professional knowledge of the capital market, continuously strengthen the awareness of duty fulfillment and risk prevention and control, and firmly establish a sense of compliance. Through independent directors, the audit committee of the board of directors and other multiple levels and dimensions, we have strengthened supervision and control in key areas such as related transactions, external guarantees, and internal controls, strictly enforced decision-making procedures and information disclosure, and effectively prevented illegal activities such as capital occupation and illegal guarantees. Scientifically formulate a salary assessment system for senior managers, reasonably link operating performance with salary levels, timely study mid- and long-term incentive measures such as equity incentives, set reasonable assessment indicators, and strengthen risk-sharing and benefit-sharing constraints between the "key minority" and the company and small and medium-sized shareholders.
Announcement is hereby made.
Board of Directors of Hanshang Group Co., Ltd.
April 29, 2026